Open AccessAdoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma
Author(s) -
Jingyu Wang,
Fang Shen,
Ying Yao,
Linlin Wang,
Yong-Jian Zhu,
Jue Hu
Publication year - 2020
Publication title -
frontiers in oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.834
H-Index - 83
ISSN - 2234-943X
DOI - 10.3389/fonc.2020.00059
Subject(s) - adoptive cell transfer , chimeric antigen receptor , medicine , immunotherapy , cancer research , melanoma , lymphoma , genetically engineered , cell therapy , cd19 , cancer , glioblastoma , adoptive immunotherapy , immunology , immune system , tumor infiltrating lymphocytes , t cell , cell , biology , gene , biochemistry , genetics
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults with very poor prognosis and few advances in its treatment. Recently, fast-growing cancer immunotherapy provides a glimmer of hope for GBM treatment. Adoptive cell therapy (ACT) aims at infusing immune cells with direct anti-tumor activity, including tumor-infiltrating lymphocyte (TIL) transfer and genetically engineered T cells transfer. For example, complete regressions in patients with melanoma and refractory lymphoma have been shown by using naturally tumor-reactive T cells and genetically engineered T cells expressing the chimeric anti-CD19 receptor, respectively. Recently, the administration of ACT showed therapeutic potentials for GBM treatment as well. In this review, we summarize the success of ACT in the treatment of cancer and provide approaches to overcome some challenges of ACT to allow its adoption for GBM treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom